

Summary of the Proposed Combination

(As required under regulation 13(1B) of the CCI (Procedure in regard to the transaction of business relating to combinations), Regulations 2011

(a) name of the parties to the combination:

- a. Vidhi Research and Development LLP (“**Vidhi**”) - Purchaser; and
- b. Pfizer Limited (“**Pfizer**”) -Seller.

(b) the type of the combination:

Acquisition of assets/business undertaking by way of acquisition of Thane Plant of Pfizer by Vidhi on a going concern basis.

(c) the area of activity of the parties to the combination; and

Activities of Vidhi

Vidhi has not started any significant operation from the date of its incorporation. Vidhi was incorporated on 15th September, 2014.

Activities of Pfizer

In India, Pfizer is engaged in manufacture and sale of pharmaceutical and consumer healthcare products. (d) the relevant market(s) to which the combination relates.

Relevant Product Market: The Proposed Transaction does not involve any transfer of products from one Party to another and hence the

relevant product market may not be required to be identified. In any case based on the precedents set by the commission in the pharmaceutical sector and in Vidhi's view the relevant product market, at its broadest, would be the pharmaceutical sector in India and the relevant product market, at its narrowest would involve only finished dosage formulations.

Relevant Geographic Market: Given that the products in the pharmaceutical sector are available all over India, the relevant geographic market for the proposed combination is the market comprising of the territory of India.